MultiHance®

 

The strength of relaxivity.

 

MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL

MultiHance® is a gadolinium based MRI contrast agent that has twice the relaxivity of conventional extracellular fluid (ECF) contrast agents, providing a marked increase in SNR to better visualize smaller lesions and improve the delineation of larger lesions 1.

 

The increase in relaxivity of MultiHance® is due to its weak, reversible interaction with plasma proteins. MultiHance® is eliminated through the kidney and, to a lesser extent, through the liver, making it the first product which is both an ECF and a hepatospecific contrast agent at the same time 2.

 

Prospective, randomized, double-blind, crossover studies have shown that the higher relaxivity of MultiHance® translates into a significantly better contrast enhancement and lesion conspicuity compared to gadopentetate dimeglumine (as well as to gadobutrol, gadoterate and gadodiamide) at equivalent doses of gadolinium in MRI of the central nervous system 3, 4, 5, 6, or into similar contrast enhancement if a half dose of MultiHance® is compared to a full dose of lower relaxivity contrast agents in MR angiography 7, 8, 9; therefore, it is less likely that high doses of MultiHance® are used in clinical practice.

 

In adult patients, MultiHance® is indicated in Europe, and in several countries in Asia and Latin America, for MRI exams of the CNS (brain and spine) and for MRI of the liver, as well as for MRA (Magnetic Resonance Angiography), where it improves the diagnostic accuracy for detecting clinically significant steno-occlusive vascular disease in adult patients with suspected or known disease of the abdominal or peripheral arteries.

 

In the US, MultiHance® is indicated for MRI of the CNS, and it has recently received approval of the FDA for contrast-enhanced MR Angiography (MRA). In this indication, MultiHance® can be used to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.

 

In Europe and in North America, MultiHance® is also indicated for MRI of the CNS in pediatric patients above 2 years of age.

 

The recommended dose of MultiHance® in MRI of the CNS, MRA, and MRI of the breast is 0.1 mmol/kg body weight, equal to 0.2 mL/kg of the 0.5 M solution; in MRI of the liver, the recommended dose is 0.05 mmol/kg body weight, equal to 0.1 mL/kg of the 0.5M solution 10. MultiHance® is also available in pre-filled syringes (PFS) of 10, 15 and 20 mL.

 

Data from a large (N = 151), crossover, randomized, double blind, intraindividual comparison study (Study MH-109) demonstrate that the dose of 0.1 mmol/kg (0.2 ml/kg) of MultiHance® provides significantly (p < 0.001) more diagnostic information than the same dose of gadopentetate in MRI of the central nervous system (CNS 3), in terms of:

 

  • Improved delineation of brain and spine lesion borders;
  • Improved definition of extent of CNS intra-axial and extra-axial tumours;
  • Improved visualization of internal morphology of CNS tumours; and
  • Improved enhancement between normal parenchyma and lesions.

 

The quantitative assessments performed in this study showed that MultiHance® provides significantly greater increase of signal intensity in CNS lesions and significantly greater lesion-to-brain contrast enhancement compared to gadopentetate. Similar results in favour of MultiHance® have also been shown in 2 other large intraindividual crossover comparative studies in MRI of the CNS, vs gadobutrol (the MERIT study) 6 and vs gadodiamide (the ENHANCE study) 4.

 

MultiHance® shows high clinical utility in MRI of the liver as well, where the high relaxivity combined with a dual route of elimination through the kidney and the liver make MultiHance® an efficient agent in liver imaging, even if administered at doses smaller than those employed for the conventional ECF agents 7.

 

In MR Angiography, MultiHance® significantly improves visualization, as well as the detection of significant steno-occlusive disease of the abdominal or peripheral arteries 10.

 

MultiHance® is well tolerated with a safety profile similar to that of other MRI gadolinium based contrast agents 8.

Contact us


Please fill out the form below and we will get back to you.

By checking this box and clicking the submit button of this page, I certify that I am a healthcare professional, and give permission for Bracco Imaging S.p.A., or parties acting on its behalf, to contact me with information regarding Bracco Imaging S.p.A., products and solutions, invitations to events and seminars, industry updates and other notifications. I understand that the information I provide will not be given to anyone outside Bracco Imaging S.p.A., except for the agents or representatives processing this request.

Different countries may have specific processes in place to handle reports of adverse reactions. To report an adverse reaction related to Bracco products, you can find specific contacts and information selecting the page "Pharmacovigilance" of your country.

DISCLAIMER

 

For any product or type of product, whether a drug or device, referenced in this website, physicians should carefully review the product's package insert, instructions for use, or user manual prior to patient administration to ensure proper utilization of the product. The local Summaries of Product Characteristics of the main Bracco Imaging products are available on line.

 

Impaired renal function

 

There have been reports of Nephrogenic Systemic Fibrosis (NSF) associated with use of some contrast agents containing gadolinium in patients with severe renal impairment (GFR<30ml/min/1.73m2). As there is a possibility that NSF may occur with MultiHance®, it should be avoided in patients with acute or chronic severe renal impairment (GFR<30ml/min/1.73m2) and in patients with acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period unless the diagnostic information is essential and cannot be obtained through other means.

 

The risk for the development of NSF in patients with moderate renal impairment is unknown, therefore MultiHance® should be used with caution in patients with moderate renal impairment (GFR 30-59ml/min/1.73m2). All patients should be screened, in particular patients over the age of 65, for renal dysfunction by obtaining a history and/or laboratory tests. Haemodialysis shortly after MultiHance® administration may be useful at removing MultiHance® from the body.

 

There is no evidence to support the initiation of haemodialysis for prevention or treatment of NSF in patients not already undergoing haemodialysis.